



AUROBINDO
Committed to healthier life!

- #1
- #2
- #10
- #150+
- #848

Largest Generic Pharma Company in the US¹ (1 in 10 prescriptions)

Largest Listed Indian Pharma Company²

Ranks amongst the Top 10 Generic companies in 8 countries of Europe

Countries with export presence³

Portfolio of US ANDA Filings



Key Therapeutic Areas:

- Oncology
- Cardiovascular
- Dermatology
- CNS
- Respiratory
- Antibiotics

50bn+ Formulation capacity

19,000 MT API capacity³

09 R&D centers (5 in India, 4 in US)

1,500+ scientists

14 Biosimilars under development

EU GMP certified manufacturing facility

29 Manufacturing facilities globally

16 Formulations
13 API & Intermediates

37,000+ Global workforce³

15,000 MT Largest Penicillin G capacity in India

Committed to becoming one of the most sustainable organizations in the pharmaceutical industry

Sustainability Goals Achieved in FY24

- 16%** Reduction in carbon footprint (from base year FY20)
- 14%** Renewable energy share (Power to Power)
- 64%** Co-processing of hazardous waste
- 100%** Reuse/recycle of non-hazardous waste

Key Subsidiaries



¹ by Rx dispensed, ² by FY24 revenue from operations, ³ in FY24